Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2021-09-21

FDA Approved: FLUOXETINE — Supplemental Application (ScieGen Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for fluoxetine by ScieGen Pharmaceuticals to update the labeling for this generic antidepressant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fluoxetine (Fluoxetine)

Snippet

SUPPL AP for FLUOXETINE (FLUOXETINE)